A diagnostically useful carrier includes a peptide including the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or a variant thereof. A kit, a composition, a detection method, use for detecting a neurological disease, a human autoantibody specifically binding to Drebrin and a therapeutic compound or combination for use in the treatment of a neurological use are also useful.

The present invention provides novel allergens isolated from grass carp Ctenopharyngodon idella, recombinant or modified polypeptides comprising such allergens, nucleic acids encoding the polypeptides as well as related compositions. Also provided are methods and kits for diagnosing fish allergy.

The present disclosure is directed to a method for reducing immunoreactivity of a food including (a) incubating a food that contains at least one protein with a cross-linking enzyme to form a food that includes at least one cross-linked protein; and (b) fermenting the food including the at least one cross-linked protein with a microorganism to form a modified food including a hydrolysate of the at least one cross-linked protein, wherein (a) is performed before (b) and wherein a level of immunoreactivity of the modified food is less than a level of immunoreactivity of an unmodified food including at least one protein. Modified foods obtained from the present method are also provided.

The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.

The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.

A method for measuring anti-PAD2 antibodies in a subject with an inflammatory or autoimmune disease, and to determine if the subject has a better prognosis for developing a more severe form of inflammation based on anti-PAD2 antibody levels. Methods for the therapeutic use of anti-PAD2 antibodies are also described.

Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO: 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Cla16), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGT-GSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.

The present invention provides medicaments for allergic diseases (atopic dermatitis, asthma, and the like), and a tool useful for pathology analysis of allergic diseases. A medicament containing as an effective component an activity modulator for suppressing inhibitory signal transduction of a CD300a-expressing myeloid cell, which activity modulator contains a substance that inhibits binding of CD300a to phosphatidyl serine, can be used for treatment or prophylaxis of an allergic disease. A CD300a gene-deficient mouse can be used as a model mouse in which the allergic disease is hardly induced after administration of a substance that induces the allergic disease, which may be used for carrying out pathology analysis of an allergic disease, or for screening of a possible candidate substance for an effective component of a therapeutic agent or prophylactic agent for the disease.

A means for predicting an infant's risk of developing an allergy to an allergen is provided. IgG1 antibody titers and IgE antibody titers against egg white in a sample of infants 6 months old or younger are measured using a DCP chip, and a scattergram is created by plotting the IgG1 antibody titer on an X axis and the IgE antibody titer on a Y axis. For data distribution divided into two blocks, a linear function applicable to the respective blocks is calculated to obtain two types of linear functions, and the risk of developing an allergy is predicted based on which block an infant belongs to.

A system and method for determining the immune status or immune cycle in a subject is provided. A sampling component for obtaining physiological data from the subject is provided together with a data storage component for storing the physiological data obtained from the subject. A processing component is provided to analyse the physiological data and thereby determine the immune status or periodicity of the immune cycle and the immune cycle of the subject. An output component for outputting the immune status or periodicity of the immune cycle, and the immune cycle of the subject and/or the future status or immune cycle of the subject is provided.